ECSP067100A - Preparación enantioselectiva del derivado de quinolina - Google Patents

Preparación enantioselectiva del derivado de quinolina

Info

Publication number
ECSP067100A
ECSP067100A EC2006007100A ECSP067100A ECSP067100A EC SP067100 A ECSP067100 A EC SP067100A EC 2006007100 A EC2006007100 A EC 2006007100A EC SP067100 A ECSP067100 A EC SP067100A EC SP067100 A ECSP067100 A EC SP067100A
Authority
EC
Ecuador
Prior art keywords
quinoline derivative
quinolin
oxy
substituted
enantioselective preparation
Prior art date
Application number
EC2006007100A
Other languages
English (en)
Inventor
Olivier Lohse
Caspar Vogel
Gerhard Penn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32799952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP067100(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP067100A publication Critical patent/ECSP067100A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/04—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D251/06—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe un proceso para la preparación de oxi-5-((R)-2-halo-1-hidroxi-etil)-(1H)-quinolin-2-onas 8-sustituidas, o solvatos aceptables de las mismas. El proceso involucra hacer reaccionar una oxi-(1H)-quinolin-2-ona 5-(a-haloacetil)-8-sustituida con un agente reductor en la presencia de un agente quiral y una base, para formar una 8-(oxi-sustituida)-5-((R)-2-halo-1-hidroxi-etil)-(1H)-quinolin-2-ona, el agente quiral una Fórmula I ó II:donde M, L, X, R1, R2, y R3 tienen los significados indicados en la especificación.
EC2006007100A 2004-06-22 2006-12-20 Preparación enantioselectiva del derivado de quinolina ECSP067100A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0413960.6A GB0413960D0 (en) 2004-06-22 2004-06-22 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP067100A true ECSP067100A (es) 2007-01-26

Family

ID=32799952

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006007100A ECSP067100A (es) 2004-06-22 2006-12-20 Preparación enantioselectiva del derivado de quinolina

Country Status (32)

Country Link
US (2) US20090054653A1 (es)
EP (1) EP1791820B1 (es)
JP (1) JP5064214B2 (es)
KR (1) KR101179302B1 (es)
CN (1) CN1968927B (es)
AR (2) AR049553A1 (es)
AT (1) ATE450512T1 (es)
AU (1) AU2005254698B2 (es)
BR (1) BRPI0512298A (es)
CA (1) CA2566388C (es)
CY (1) CY1109884T1 (es)
DE (1) DE602005018076D1 (es)
DK (1) DK1791820T3 (es)
EC (1) ECSP067100A (es)
ES (1) ES2337273T3 (es)
GB (1) GB0413960D0 (es)
HR (1) HRP20100087T1 (es)
IL (1) IL179600A (es)
MA (1) MA28687B1 (es)
MX (1) MXPA06014695A (es)
MY (1) MY142051A (es)
NO (1) NO339079B1 (es)
NZ (1) NZ551276A (es)
PE (1) PE20060304A1 (es)
PL (1) PL1791820T3 (es)
PT (1) PT1791820E (es)
RU (1) RU2383534C2 (es)
SI (1) SI1791820T1 (es)
TN (1) TNSN06408A1 (es)
TW (1) TWI347317B (es)
WO (1) WO2005123684A2 (es)
ZA (1) ZA200609257B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2044025E (pt) 2006-06-30 2012-12-17 Novartis Ag Derivados de quinolinona e suas composições farmacêuticas
EP1914227A1 (en) * 2006-08-31 2008-04-23 Novartis AG Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
US8877930B2 (en) 2009-11-04 2014-11-04 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
WO2011109276A1 (en) 2010-03-01 2011-09-09 Massachussets Institute Of Technology Epoxidation catalysts
PT2593452T (pt) 2010-07-14 2017-04-24 Novartis Ag Compostos heterocíclicos agonistas do receptor ip
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US20150005311A1 (en) 2012-01-13 2015-01-01 Novartis Ag IP receptor agonist heterocyclic compounds
US9174985B2 (en) 2012-01-13 2015-11-03 Novartis Ag Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists
US20140357641A1 (en) 2012-01-13 2014-12-04 Novartis Ag IP receptor agonist heterocyclic compounds
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
UY34572A (es) 2012-01-13 2013-09-02 Novartis Ag Compuestos heterocíclicos agonistas del receptor ip
WO2014008640A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
EP3138837B1 (en) 2012-09-21 2021-11-24 Crystal Pharma, S.A.U. Indacaterol free base in solid form
WO2014044288A1 (en) 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
US9630945B2 (en) 2012-12-19 2017-04-25 Novartis Ag Autotaxin inhibitors
CN105189500A (zh) 2013-02-13 2015-12-23 诺华股份有限公司 Ip受体激动剂杂环化合物
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
AU2014229361B2 (en) 2013-03-14 2016-08-04 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
EP2978745B1 (en) 2013-03-27 2017-03-15 Laboratorios Lesvi, S.L. Process for the manufacture of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one
AP2016009020A0 (en) 2013-07-18 2016-02-29 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
US20160168119A1 (en) 2013-07-18 2016-06-16 Novartis Ag Autotaxin inhibitors
PL3092217T3 (pl) 2014-01-09 2020-11-16 Davuluri, Ramamohan Rao Nowy sposób wytwarzania indakaterolu lub jego farmaceutycznie dopuszczalnych soli
MX2016012641A (es) 2014-03-27 2016-12-14 Novartis Ag Dispersiones solidas secas en aceite en agua por aspersion para inhalacion de ingredientes farmaceuticos activos.
EP3134398A1 (en) 2014-04-24 2017-03-01 Novartis Ag Autotaxin inhibitors
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
KR101769204B1 (ko) * 2015-08-04 2017-08-17 씨제이헬스케어 주식회사 크로마놀 유도체의 신규한 제조방법
ES2747905T3 (es) 2015-09-29 2020-03-12 Inke Sa Solvato mixto de L-tartrato de (R)-5-[2-(5,6-dietilindan-2-ilamino)-1-hidroxietil]-8-hidroxi-1H-quinolin-2-ona
CN107394260B (zh) 2016-05-17 2020-06-09 财团法人工业技术研究院 金属离子电池
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN114591236A (zh) * 2020-12-02 2022-06-07 四川海思科制药有限公司 一种茚达特罗的改进制备方法
CN113731406B (zh) * 2021-10-12 2023-07-28 南京工业大学 一种提高钯碳活性加氢脱除保护基的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
CZ296163B6 (cs) * 1996-05-20 2006-01-11 Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
TWI324151B (en) * 2003-04-02 2010-05-01 Novartis Ag Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones

Also Published As

Publication number Publication date
IL179600A0 (en) 2007-05-15
EP1791820A2 (en) 2007-06-06
HK1105121A1 (en) 2008-02-01
ZA200609257B (en) 2008-07-30
HRP20100087T1 (hr) 2010-06-30
IL179600A (en) 2011-11-30
MA28687B1 (fr) 2007-06-01
AR082981A2 (es) 2013-01-23
US20120220775A1 (en) 2012-08-30
RU2007102228A (ru) 2008-07-27
JP5064214B2 (ja) 2012-10-31
MXPA06014695A (es) 2007-02-12
WO2005123684A3 (en) 2006-06-01
PL1791820T3 (pl) 2010-05-31
EP1791820B1 (en) 2009-12-02
US20090054653A1 (en) 2009-02-26
GB0413960D0 (en) 2004-07-28
WO2005123684A2 (en) 2005-12-29
ES2337273T3 (es) 2010-04-22
SI1791820T1 (sl) 2010-04-30
CN1968927A (zh) 2007-05-23
DE602005018076D1 (de) 2010-01-14
AU2005254698A1 (en) 2005-12-29
ATE450512T1 (de) 2009-12-15
TW200615265A (en) 2006-05-16
MY142051A (en) 2010-08-30
CN1968927B (zh) 2010-07-21
PE20060304A1 (es) 2006-05-19
JP2008503526A (ja) 2008-02-07
KR20070029752A (ko) 2007-03-14
PT1791820E (pt) 2010-02-23
KR101179302B1 (ko) 2012-09-03
CY1109884T1 (el) 2014-09-10
AR049553A1 (es) 2006-08-16
CA2566388C (en) 2013-04-16
TWI347317B (en) 2011-08-21
RU2383534C2 (ru) 2010-03-10
TNSN06408A1 (en) 2008-02-22
NO339079B1 (no) 2016-11-07
NZ551276A (en) 2010-06-25
CA2566388A1 (en) 2005-12-29
NO20070400L (no) 2007-03-21
DK1791820T3 (da) 2010-04-06
AU2005254698B2 (en) 2008-09-25
BRPI0512298A (pt) 2008-03-25

Similar Documents

Publication Publication Date Title
ECSP067100A (es) Preparación enantioselectiva del derivado de quinolina
UY29246A1 (es) Nuevos compuestos
ES2524966T3 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
IS2520B (is) Nikótínamíð afleiður nytsamlegar sem P38 hindrar
GB0402137D0 (en) Novel compounds
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
CO6270257A2 (es) Derivados de piridazinona
PE20091623A1 (es) DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
ECSP10010361A (es) Derivados de piridazinona
ECSP088598A (es) Derivados de piridazinona
UY38952A (es) Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y composiciones farmacéu-ticas que las contienen
TW200608977A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
MX2009006864A (es) Inhibidores novedosos de c jun-n-terminal cinasas.
CR9881A (es) Polimorfos de la sal benzoato de 2-[[6-[(3r)-3amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y metodos de uso para los mismos
MXPA05012894A (es) Benzofuranos 3-sustituidos como agentes terapeuticos.
PE20060818A1 (es) Compuestos de triazoloquinoleina que aumentan la produccion de apolipoproteina a-1
NO20071574L (no) Arylsulfonylstilbenderivater for behandling av insomni og beslektede tilstander.
NO20073839L (no) Kinolinderivat, fremgangsmate for fremstilling og anvendelse av dette, og legemiddel inneholdende dette
ATE368666T1 (de) Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren
TW200616976A (en) Pyrimidine derivatives
MXPA05012953A (es) Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
PE20070795A1 (es) Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
TW200628153A (en) Novel compounds
DE60127131D1 (de) Tricyclische imidazopyridine